WILMINGTON, Del. / Nov 08, 2023 / Business Wire / Phreesia today announced its patient intake platform and data centers have earned certified status by HITRUST for information security.
We believe HITRUST Risk-based, 2-year (r2) Certified status demonstrates that Phreesia’s intake platform and data centers have met demanding regulatory compliance and industry-defined requirements and are appropriately managing risk. This achievement places Phreesia in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks, and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.
“At Phreesia, we’re dedicated to upholding the highest security and compliance standards, and this recertification is a welcome recognition of those efforts” said Evan Roberts, Chief Operating Officer, Phreesia. “As we continue to grow and scale, we want our clients to be assured that we’re a trusted partner and responsible steward of their data. HITRUST certification gives them confidence that we take our commitment incredibly seriously.”
“HITRUST Certification is globally recognized as validation that information security and privacy controls are effective and compliant with various regulations. HITRUST Certification is considered the gold standard because of the comprehensiveness and applicability of the control requirements, depth of the assurance process, and level of oversight that ensures accuracy,” said Jeremy Huval, Chief Innovation Officer, HITRUST. “Individually, each element exceeds most other programs, and collectively they make HITRUST Certification the most comprehensive, transparent, consistent, and highest quality assessment available.”
About Phreesia
Phreesia is a trusted leader in patient activation, giving providers, health plans, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 120 million patient visits in 2022–more than 1 in 10 visits across the U.S.–scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit www.phreesia.com.
Last Trade: | US$27.60 |
Daily Change: | 0.88 3.29 |
Daily Volume: | 361,477 |
Market Cap: | US$1.640B |
May 28, 2025 March 12, 2025 December 09, 2024 October 28, 2024 October 01, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load